Our data are consistent with an alternative explanation for the lack of efficacy of MEK inhibitors in colorectal cancers expressing mutant K-RAS – that there exists an alternate/parallel pathway downstream of B-RAF that mediates K-RAS-induced oncogenicity. This evidence concerns the gene KRAS and colorectal cancer.